Chitosan‐Fe ( III III ) Complex as a Phosphate Chelator in Uraemic Rats: A Novel Treatment Option

摘要

Abstract Phosphate retention and hyperphosphataemia are associated with increased mortality in patients with chronic kidney disease ( CKD ). We tested the use of cross‐linked iron chitosan III ( CH ‐FeCl) as a potential phosphate chelator in rats with CKD . We evaluated 96 animals, divided equally into four groups (control, CKD , CH ‐FeCl and CKD / CH ‐FeCl), over 7 weeks. We induced CKD by feeding animals an adenine‐enriched diet (0.75% in the first 4 weeks and 0.1% in the following 3 weeks). We administered 30 mg/kg daily of the test polymer, by gavage, from the third week until the end of the study. All animals received a diet supplemented with 1% phosphorus. Uraemia was confirmed by the increase in serum creatinine in week 4 (36.24 ± 18.56 versus 144.98 ± 22.1 μmol/L; p = 0.0001) and week 7 (41.55 ± 22.1 versus 83.98 ± 18.56 μmol/L; p = 0.001) in CKD animals. Rats from the CKD group treated with CH ‐FeCl had a 54.5% reduction in serum phosphate (6.10 ± 2.23 versus 2.78 ± 0.55 mmol/L) compared to a reduction of 25.6% in the untreated CKD group (4.75 ± 1.45 versus 3.52 ± 0.74 mmol/L, p = 0.021), between week 4 and week 7. At week 7, renal function in both CKD groups was similar (serum creatinine: 83.98 ± 18.56 versus 83.10 ± 23.87 μmol/L, p = 0.888); however, the CH ‐FeCl‐treated rats had a reduction in phosphate overload measured by fractional phosphate excretion ( FEP i) (0.71 ± 0.2 versus 0.4 ± 0.16, p = 0.006) compared to the untreated CKD group. Our study demonstrated that CH ‐FeCl had an efficient chelating action on phosphate.